Clinical Trials Sponsored by Bicara Therapeutics

Total 6380 results

Bicara Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Pancreas Cancer | Squamous Cell Carcinoma of the Lung | Cutaneous Squamous Cell Carcinoma | Squamous Cell Carcinoma of... and other conditions

United States, Canada
Zucara Therapeutics Inc.

Recruiting

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes (ZONE)

Type 1 Diabetes Mellitus With Hypoglycemia

United States, Canada
Zucara Therapeutics Inc.

Terminated

Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus

Hypoglycemia | Type 1 Diabetes

Canada
Cidara Therapeutics Inc.

Completed

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Cidara Therapeutics Inc.

Completed

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (STRIVE)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis

United States, Spain, Belgium, Russian Federation, Greece, Bulgaria, Canada, Hungary, Italy, Romania
Cidara Therapeutics Inc.

Completed

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Cidara Therapeutics Inc.

Completed

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Cidara Therapeutics Inc.

Recruiting

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis | Invasive Fungal Disease | Pneumocystis | Mold Infection | Prophylaxis of Invasive Fungal Infections | Aspergillus

United States, Germany, France, Belgium, Canada, Italy, Spain, United Kingdom, Turkey, Switzerland
Cidara Therapeutics Inc.

Completed

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

Mycoses | Candidemia | Fungal Infection | Invasive Candidiases

United States, Israel, Spain, Korea, Republic of, Taiwan, Singapore, Thailand, Australia, China, Turkey, Belgium, Germany, France, Argentina, Bulgaria, Colombia, Greece, Italy
Cidara Therapeutics Inc.

Completed

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Biora Therapeutics, Inc.

Recruiting

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

Healthy

United States
Vidara Therapeutics Research Ltd

Unknown

Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers (FLS)

Adverse Effects in the Therapeutic Use of Interferon

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

Influenza

United Kingdom
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Pruritus | Notalgia Paresthetica

United States, Canada
Cara Therapeutics, Inc.

Approved for marketing

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

Uremic Pruritus
Cara Therapeutics, Inc.

Completed

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2)

Uremic Pruritus

United States, Canada, Czechia, Australia, Germany, Hungary, Korea, Republic of, New Zealand, Poland, Taiwan, United Kingdom
Cara Therapeutics, Inc.

Completed

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Post Abdominal Surgery Pain

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Postoperative Pain

United States
Cara Therapeutics, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Pruritus | Notalgia Paresthetica

United States, Poland, Spain, Canada, Germany
Cara Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KIND-1)

Pruritus | Atopic Dermatitis

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Cholestatic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
Cara Therapeutics, Inc.

Completed

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Arthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Cara Therapeutics, Inc.

Completed

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Healthy

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Cara Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

Acute Pain

United States
Cara Therapeutics, Inc.

Recruiting

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States, Korea, Republic of, Australia, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Argentina, Brazil, Mexico
Cara Therapeutics, Inc.

Completed

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Hemodialysis

United States
Cara Therapeutics, Inc.

Completed

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Czechia, Hungary, Poland
Cara Therapeutics, Inc.

Completed

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Puerto Rico
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Healthy | Hemodialysis

United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
iCell Gene Therapeutics
iCAR Bio Therapeutics Ltd. China

Recruiting

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

China
Nobel Biocare

Recruiting

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

Marginal Bone Level Change

Denmark
Nobel Biocare

Terminated

Nobel Procera Crown Shaded Zirconia and NobelProceraTM Full Contour Crown IPS e.Max CAD

Partial Edentulism

Germany
Nobel Biocare

Terminated

A 5 Year Clinical Investigation on Creos Xenoprotect (CXP)

Implant

Germany
Nobel Biocare

Completed

T-116_Procera-Bridge Zirconia - A Clinical Study

Partial Edentulism
Nobel Biocare

Completed

Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants

Partial Edentulism | Complete Edentulism
Nobel Biocare

Unknown

Extra Short Implants Brånemark System® RP Ø4.5x4.5 mm Implants

Healthy Volunteers With Severely Resorbed Jaws in Need of an Implant Supported Restoration

Germany
Incara Pharmaceuticals

Completed

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Nobel Biocare

Completed

Study Assessing the Safety and Effectiveness of the Nobel Biocare N1 Concept System. (Evolution)

Dental Implant

Hungary, Italy, Netherlands

Clinical Trials Sponsored by Bicara Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations